Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
-
Novo Nordisk today announced data demonstrating that Wegovy® delivers substantial and consistent weight-loss results for women.
-
Higher-dose Wegovy led to up to 28% weight loss, mainly from fat, with muscle preserved, new trial data show.
-
The strong performance of Wegovy® and continued growth in International Operations have led us to raise our 2026 guidance for both adjusted sales and ...
-
UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions relate
-
Novo Nordisk will present new clinical data and real-world evidence at the European Congress on Obesity, 12–15 May in Istanbul, Turkey.
-
Wegovy® injection is the first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
-
NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in
-
US FDA has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term.
-
Final EU approval of high-maintenance dose of Wegovy. The new dose gives healthcare professionals even more flexibility to tailor treatment.